CleftGeneDB-Search

Gene: IGF2

Basic information

Tag	Content
Uniprot ID	P01344; B3KX48; B7WP08; C9JAF2; E3UN45; P78449; Q14299; Q1WM26; Q9UC68; Q9UC69;
Entrez ID	3481
Genbank protein ID	CAA27156.1; AAA52536.1; AAB34155.1; BAG54360.1; ADO21454.1; CAA27249.1; AAM51825.1; AAA52443.1; CAA29517.1; CAA30717.1; CAA25426.1; ABD93451.1; AAH00531.1; AAA52545.1; AAA52544.1; AAA60088.1; AAP35659.1; CAA27157.1; EAX02485.1; CAA27155.1; CAA29516.1; CAA29518.1; AAG17220.1;
Genbank nucleotide ID	NM_001291861.2; NM_001007139.5; NM_001291862.2; NM_000612.5; NM_001127598.2;
Ensembl protein ID	ENSP00000370799; ENSP00000370796; ENSP00000370813; ENSP00000370802; ENSP00000391826; ENSP00000414497; ENSP00000402047;
Ensembl nucleotide ID	ENSG00000167244
Gene name	Insulin-like growth factor II
Gene symbol	IGF2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	The insulin-like growth factors possess growth-promoting activity. Major fetal growth hormone in mammals. Plays a key role in regulating fetoplacental development. IGF-II is influenced by placental lactogen. Also involved in tissue differentiation. Positively regulates myogenic transcription factor MYOD1 function by facilitating the recruitment of transcriptional coactivators, thereby controlling muscle terminal differentiation (By similarity). In adults, involved in glucose metabolism in adipose tissue, skeletal muscle and liver (Probable). Acts as a ligand for integrin which is required for IGF2 signaling (PubMed:28873464).
Sequence	MGIPMGKSML VLLTFLAFAS CCIAAYRPSE TLCGGELVDT LQFVCGDRGF YFSRPASRVS 60 RRSRGIVEEC CFRSCDLALL ETYCATPAKS ERDVSTPPTV LPDNFPRYPV GKFFQYDTWK 120 QSTQRLRRGL PALLRARRGH VLAKELEAFR EAKRHRPLIA LPTQDPAHGG APPEMASNRK 180

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1GF2
1IGL
2L29
2V5P
3E4Z
3KR3
5L3L
5L3M
5L3N
6UM2
1IGL

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Developmental stage	Species	Evidence	Details
1:1 ortholog	IGF2	281240	P07456			Bos taurus	Prediction	More>>
1:1 ortholog	IGF2	100861277	Q153G7			Capra hircus	Prediction	More>>
1:1 ortholog	IGF2	3481	P01344			Homo sapiens	Prediction	More>>
1:1 ortholog	Igf2	16002	P09535	CPO	E14.5, E18.5	Mus musculus	Publication	More>>
1:1 ortholog	Igf2	24483	A0A0G2JTA6			Rattus norvegicus	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs781634507	p.Gly2Val	missense variant	-	NC_000011.10:g.2135519C>A	ExAC,TOPMed,gnomAD
rs781634507	p.Gly2Glu	missense variant	-	NC_000011.10:g.2135519C>T	ExAC,TOPMed,gnomAD
rs1340808708	p.Ile3Phe	missense variant	-	NC_000011.10:g.2135517T>A	gnomAD
rs1333440627	p.Pro4Ala	missense variant	-	NC_000011.10:g.2135514G>C	gnomAD
rs1172508915	p.Met5Val	missense variant	-	NC_000011.10:g.2135511T>C	TOPMed
rs757907236	p.Met5Arg	missense variant	-	NC_000011.10:g.2135510A>C	ExAC,TOPMed,gnomAD
rs752191866	p.Gly6Val	missense variant	-	NC_000011.10:g.2135507C>A	ExAC,gnomAD
rs146334276	p.Lys7Asn	missense variant	-	NC_000011.10:g.2135503C>A	ESP,ExAC,TOPMed,gnomAD
rs764865819	p.Lys7Thr	missense variant	-	NC_000011.10:g.2135504T>G	ExAC,gnomAD
RCV000186560	p.Ser8Ter	nonsense	Growth restriction, severe, with distinctive facies (GRDF)	NC_000011.10:g.2135501G>T	ClinVar
rs869320620	p.Ser8Ter	stop gained	-	NC_000011.10:g.2135501G>T	TOPMed,gnomAD
rs869320620	p.Ser8Leu	missense variant	-	NC_000011.10:g.2135501G>A	TOPMed,gnomAD
rs1294135404	p.Met9Leu	missense variant	-	NC_000011.10:g.2135499T>G	TOPMed
rs984257990	p.Leu10Pro	missense variant	-	NC_000011.10:g.2135495A>G	TOPMed,gnomAD
rs1361412373	p.Leu10Val	missense variant	-	NC_000011.10:g.2135496G>C	TOPMed
rs767507381	p.Phe15Leu	missense variant	-	NC_000011.10:g.2135481A>G	ExAC,TOPMed,gnomAD
rs1240151267	p.Leu16Trp	missense variant	-	NC_000011.10:g.2135477A>C	gnomAD
rs142012621	p.Ser20Trp	missense variant	-	NC_000011.10:g.2135465G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs142012621	p.Ser20Leu	missense variant	-	NC_000011.10:g.2135465G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
RCV000491853	p.Tyr26Ter	nonsense	Russell-Silver syndrome (SRS)	NC_000011.10:g.2135446G>C	ClinVar
rs1064794050	p.Tyr26Ter	stop gained	-	NC_000011.10:g.2135446G>C	TOPMed
rs1256437532	p.Tyr26Phe	missense variant	-	NC_000011.10:g.2135447T>A	gnomAD
RCV000479354	p.Tyr26Ter	nonsense	-	NC_000011.10:g.2135446G>C	ClinVar
rs1356855570	p.Arg27His	missense variant	-	NC_000011.10:g.2135444C>T	TOPMed,gnomAD
rs1230176657	p.Arg27Cys	missense variant	-	NC_000011.10:g.2135445G>A	TOPMed,gnomAD
rs1356855570	p.Arg27Leu	missense variant	-	NC_000011.10:g.2135444C>A	TOPMed,gnomAD
rs1230176657	p.Arg27Ser	missense variant	-	NC_000011.10:g.2135445G>T	TOPMed,gnomAD
RCV000414320	p.Cys33Arg	missense variant	-	NC_000011.10:g.2135427A>G	ClinVar
RCV000412860	p.Cys33Ter	nonsense	-	NC_000011.10:g.2135425G>T	ClinVar
rs1057518115	p.Cys33Arg	missense variant	-	NC_000011.10:g.2135427A>G	-
rs553443857	p.Cys33Ter	stop gained	-	NC_000011.10:g.2135425G>T	ExAC,gnomAD
rs747135996	p.Val44Ile	missense variant	-	NC_000011.10:g.2135394C>T	ExAC,gnomAD
rs778465733	p.Arg48Leu	missense variant	-	NC_000011.10:g.2135381C>A	ExAC,TOPMed,gnomAD
rs778465733	p.Arg48His	missense variant	-	NC_000011.10:g.2135381C>T	ExAC,TOPMed,gnomAD
rs1018841144	p.Arg48Cys	missense variant	-	NC_000011.10:g.2135382G>A	TOPMed,gnomAD
rs1268424766	p.Ala56Val	missense variant	-	NC_000011.10:g.2133656G>A	TOPMed
rs1212009594	p.Ala56Thr	missense variant	-	NC_000011.10:g.2133657C>T	TOPMed
rs1315236317	p.Ser57Asn	missense variant	-	NC_000011.10:g.2133653C>T	gnomAD
rs761163170	p.Arg58His	missense variant	-	NC_000011.10:g.2133650C>T	ExAC,gnomAD
rs773449505	p.Arg61His	missense variant	-	NC_000011.10:g.2133641C>T	ExAC,gnomAD
rs768105151	p.Arg62Leu	missense variant	-	NC_000011.10:g.2133638C>A	ExAC,gnomAD
rs768105151	p.Arg62His	missense variant	-	NC_000011.10:g.2133638C>T	ExAC,gnomAD
rs369844466	p.Arg64His	missense variant	-	NC_000011.10:g.2133632C>T	ESP,TOPMed,gnomAD
rs762200142	p.Arg64Cys	missense variant	-	NC_000011.10:g.2133633G>A	ExAC,TOPMed,gnomAD
rs150610908	p.Gly65Asp	missense variant	-	NC_000011.10:g.2133629C>T	ESP
rs1472622300	p.Glu69Gln	missense variant	-	NC_000011.10:g.2133618C>G	TOPMed
RCV000731499	p.Cys71Arg	missense variant	-	NC_000011.10:g.2133612A>G	ClinVar
rs1383314827	p.Arg73Cys	missense variant	-	NC_000011.10:g.2133606G>A	gnomAD
rs745308728	p.Arg73His	missense variant	-	NC_000011.10:g.2133605C>T	ExAC,TOPMed,gnomAD
rs746888392	p.Thr82Met	missense variant	-	NC_000011.10:g.2133578G>A	ExAC,TOPMed,gnomAD
rs748117121	p.Thr86Ile	missense variant	-	NC_000011.10:g.2133566G>A	ExAC,gnomAD
rs758164144	p.Thr86Pro	missense variant	-	NC_000011.10:g.2133567T>G	ExAC,gnomAD
rs755066389	p.Pro87Ala	missense variant	-	NC_000011.10:g.2133564G>C	ExAC,gnomAD
rs755066389	p.Pro87Thr	missense variant	-	NC_000011.10:g.2133564G>T	ExAC,gnomAD
rs1290256492	p.Pro87His	missense variant	-	NC_000011.10:g.2133563G>T	gnomAD
rs753904854	p.Ala88Thr	missense variant	-	NC_000011.10:g.2133561C>T	ExAC,gnomAD
rs753904854	p.Ala88Pro	missense variant	-	NC_000011.10:g.2133561C>G	ExAC,gnomAD
rs750845881	p.Asp93Asn	missense variant	-	NC_000011.10:g.2133546C>T	ExAC,gnomAD
rs1457247306	p.Ser95Leu	missense variant	-	NC_000011.10:g.2133539G>A	TOPMed,gnomAD
rs775000758	p.Pro97Leu	missense variant	-	NC_000011.10:g.2133533G>A	ExAC,gnomAD
rs143785521	p.Pro98Leu	missense variant	-	NC_000011.10:g.2133530G>A	ESP,ExAC,TOPMed,gnomAD
rs143785521	p.Pro98Gln	missense variant	-	NC_000011.10:g.2133530G>T	ESP,ExAC,TOPMed,gnomAD
rs369122420	p.Pro102Leu	missense variant	-	NC_000011.10:g.2133518G>A	ESP,ExAC,TOPMed,gnomAD
rs771744589	p.Arg107Ile	missense variant	-	NC_000011.10:g.2133210C>A	ExAC,gnomAD
rs774104462	p.Pro109Thr	missense variant	-	NC_000011.10:g.2133205G>T	ExAC,gnomAD
rs376878619	p.Val110Met	missense variant	-	NC_000011.10:g.2133202C>T	ESP,ExAC,TOPMed,gnomAD
rs769766130	p.Val110Ala	missense variant	-	NC_000011.10:g.2133201A>G	ExAC,gnomAD
rs376878619	p.Val110Leu	missense variant	-	NC_000011.10:g.2133202C>A	ESP,ExAC,TOPMed,gnomAD
rs745901132	p.Gly111Val	missense variant	-	NC_000011.10:g.2133198C>A	ExAC,gnomAD
rs1301744036	p.Phe114Ser	missense variant	-	NC_000011.10:g.2133189A>G	gnomAD
rs14367	p.Lys120Asn	missense variant	-	NC_000011.10:g.2133170C>A	UniProt,dbSNP
VAR_011959	p.Lys120Asn	missense variant	-	NC_000011.10:g.2133170C>A	UniProt
rs14367	p.Lys120Asn	missense variant	-	NC_000011.10:g.2133170C>A	-
rs781325329	p.Arg125Cys	missense variant	-	NC_000011.10:g.2133157G>A	ExAC,gnomAD
rs757547834	p.Arg125His	missense variant	-	NC_000011.10:g.2133156C>T	ExAC,TOPMed,gnomAD
rs1191719522	p.Arg127Leu	missense variant	-	NC_000011.10:g.2133150C>A	TOPMed,gnomAD
rs1191719522	p.Arg127His	missense variant	-	NC_000011.10:g.2133150C>T	TOPMed,gnomAD
rs1372848092	p.Arg127Cys	missense variant	-	NC_000011.10:g.2133151G>A	gnomAD
rs1257021707	p.Pro131Leu	missense variant	-	NC_000011.10:g.2133138G>A	gnomAD
rs530101369	p.Leu133Val	missense variant	-	NC_000011.10:g.2133133G>C	1000Genomes,gnomAD
rs530101369	p.Leu133Phe	missense variant	-	NC_000011.10:g.2133133G>A	1000Genomes,gnomAD
rs1459983752	p.Arg135Cys	missense variant	-	NC_000011.10:g.2133127G>A	TOPMed,gnomAD
rs1260271030	p.Arg135His	missense variant	-	NC_000011.10:g.2133126C>T	gnomAD
rs778304668	p.Ala136Gly	missense variant	-	NC_000011.10:g.2133123G>C	ExAC,TOPMed,gnomAD
rs1338558695	p.Arg137Gly	missense variant	-	NC_000011.10:g.2133121G>C	TOPMed,gnomAD
rs1268163024	p.Arg137His	missense variant	-	NC_000011.10:g.2133120C>T	gnomAD
rs1338558695	p.Arg137Cys	missense variant	-	NC_000011.10:g.2133121G>A	TOPMed,gnomAD
rs371682005	p.Arg138Gly	missense variant	-	NC_000011.10:g.2133118G>C	ESP,ExAC,TOPMed,gnomAD
rs371682005	p.Arg138Trp	missense variant	-	NC_000011.10:g.2133118G>A	ESP,ExAC,TOPMed,gnomAD
rs1413387573	p.Arg138Gln	missense variant	-	NC_000011.10:g.2133117C>T	TOPMed
rs369452652	p.Gly139Val	missense variant	-	NC_000011.10:g.2133114C>A	ESP,ExAC,TOPMed,gnomAD
rs369452652	p.Gly139Asp	missense variant	-	NC_000011.10:g.2133114C>T	ESP,ExAC,TOPMed,gnomAD
rs375129654	p.Val141Leu	missense variant	-	NC_000011.10:g.2133109C>G	ESP,ExAC,TOPMed,gnomAD
rs375129654	p.Val141Met	missense variant	-	NC_000011.10:g.2133109C>T	ESP,ExAC,TOPMed,gnomAD
rs1006709496	p.Leu142Phe	missense variant	-	NC_000011.10:g.2133106G>A	TOPMed
rs200836416	p.Ala143Thr	missense variant	-	NC_000011.10:g.2133103C>T	1000Genomes,ExAC,TOPMed,gnomAD
rs200836416	p.Ala143Ser	missense variant	-	NC_000011.10:g.2133103C>A	1000Genomes,ExAC,TOPMed,gnomAD
rs761436263	p.Lys144Gln	missense variant	-	NC_000011.10:g.2133100T>G	ExAC,gnomAD
rs1396314297	p.Leu146Pro	missense variant	-	NC_000011.10:g.2133093A>G	gnomAD
rs150866176	p.Glu147Lys	missense variant	-	NC_000011.10:g.2133091C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs150866176	p.Glu147Gln	missense variant	-	NC_000011.10:g.2133091C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs139194127	p.Glu147Asp	missense variant	-	NC_000011.10:g.2133089C>G	ESP,ExAC,TOPMed,gnomAD
rs1291850589	p.Glu147Val	missense variant	-	NC_000011.10:g.2133090T>A	TOPMed
rs368814253	p.Ala148Glu	missense variant	-	NC_000011.10:g.2133087G>T	ESP,ExAC,TOPMed,gnomAD
rs368814253	p.Ala148Val	missense variant	-	NC_000011.10:g.2133087G>A	ESP,ExAC,TOPMed,gnomAD
rs747266091	p.Glu151Lys	missense variant	-	NC_000011.10:g.2133079C>T	ExAC,gnomAD
rs778075715	p.Ala152Pro	missense variant	-	NC_000011.10:g.2133076C>G	ExAC,gnomAD
rs146962483	p.Arg154His	missense variant	-	NC_000011.10:g.2133069C>T	ESP,ExAC,TOPMed,gnomAD
rs146962483	p.Arg154Pro	missense variant	-	NC_000011.10:g.2133069C>G	ESP,ExAC,TOPMed,gnomAD
rs758849172	p.Arg154Cys	missense variant	-	NC_000011.10:g.2133070G>A	ExAC,TOPMed,gnomAD
rs61732764	p.Arg156His	missense variant	-	NC_000011.10:g.2133063C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1243657106	p.Arg156Cys	missense variant	-	NC_000011.10:g.2133064G>A	TOPMed,gnomAD
RCV000598672	p.Pro157Ter	nonsense	-	NC_000011.10:g.2133061del	ClinVar
rs755482890	p.Pro157Ala	missense variant	-	NC_000011.10:g.2133061G>C	ExAC,TOPMed,gnomAD
rs755482890	p.Pro157Thr	missense variant	-	NC_000011.10:g.2133061G>T	ExAC,TOPMed,gnomAD
rs755482890	p.Pro157Ser	missense variant	-	NC_000011.10:g.2133061G>A	ExAC,TOPMed,gnomAD
rs1407468267	p.Ile159Leu	missense variant	-	NC_000011.10:g.2133055T>G	gnomAD
rs1032405005	p.Ala160Val	missense variant	-	NC_000011.10:g.2133051G>A	gnomAD
rs1226943034	p.Leu161Pro	missense variant	-	NC_000011.10:g.2133048A>G	gnomAD
rs763681027	p.Asp165Glu	missense variant	-	NC_000011.10:g.2133035G>C	ExAC,gnomAD
rs1469636028	p.Asp165Gly	missense variant	-	NC_000011.10:g.2133036T>C	gnomAD
rs377316111	p.Ala167Thr	missense variant	-	NC_000011.10:g.2133031C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs377316111	p.Ala167Ser	missense variant	-	NC_000011.10:g.2133031C>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs554804044	p.Gly169Trp	missense variant	-	NC_000011.10:g.2133025C>A	1000Genomes,ExAC,gnomAD
rs554804044	p.Gly169Arg	missense variant	-	NC_000011.10:g.2133025C>T	1000Genomes,ExAC,gnomAD
rs747026832	p.Gly170Asp	missense variant	-	NC_000011.10:g.2133021C>T	ExAC,gnomAD
rs771138084	p.Gly170Ser	missense variant	-	NC_000011.10:g.2133022C>T	ExAC,TOPMed,gnomAD
rs773624887	p.Ala171Val	missense variant	-	NC_000011.10:g.2133018G>A	ExAC,gnomAD
rs1347870712	p.Ala171Thr	missense variant	-	NC_000011.10:g.2133019C>T	gnomAD
rs1322797114	p.Pro172Ser	missense variant	-	NC_000011.10:g.2133016G>A	gnomAD
rs1050342	p.Pro173Arg	missense variant	-	NC_000011.10:g.2133012G>C	ExAC,TOPMed,gnomAD
rs11545014	p.Pro173Ser	missense variant	-	NC_000011.10:g.2133013G>A	ExAC,TOPMed,gnomAD
rs1050342	p.Pro173Leu	missense variant	-	NC_000011.10:g.2133012G>A	ExAC,TOPMed,gnomAD
rs11545014	p.Pro173Ala	missense variant	-	NC_000011.10:g.2133013G>C	ExAC,TOPMed,gnomAD
rs1050342	p.Pro173Gln	missense variant	-	NC_000011.10:g.2133012G>T	ExAC,TOPMed,gnomAD
rs749836523	p.Glu174Asp	missense variant	-	NC_000011.10:g.2133008C>G	ExAC,gnomAD
RCV000520721	p.Glu174Ter	frameshift	-	NC_000011.10:g.2133018dup	ClinVar
rs1363016357	p.Ala176Thr	missense variant	-	NC_000011.10:g.2133004C>T	gnomAD
rs1160380880	p.Ser177Arg	missense variant	-	NC_000011.10:g.2132999G>T	TOPMed,gnomAD
rs1421347729	p.Asn178Ser	missense variant	-	NC_000011.10:g.2132997T>C	gnomAD
rs1014211286	p.Arg179Trp	missense variant	-	NC_000011.10:g.2132995G>A	TOPMed,gnomAD
rs1014211286	p.Arg179Gly	missense variant	-	NC_000011.10:g.2132995G>C	TOPMed,gnomAD
rs565575035	p.Arg179Gln	missense variant	-	NC_000011.10:g.2132994C>T	ExAC,gnomAD
rs12993	p.Lys180Asn	missense variant	-	NC_000011.10:g.2132990C>A	UniProt,dbSNP
VAR_011961	p.Lys180Asn	missense variant	-	NC_000011.10:g.2132990C>A	UniProt
rs12993	p.Lys180Asn	missense variant	-	NC_000011.10:g.2132990C>A	-

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0000768	Congenital Abnormality	group	BEFREE
C0000786	Spontaneous abortion	phenotype	CTD_human;LHGDN
C0000822	Abortion, Tubal	disease	CTD_human
C0001418	Adenocarcinoma	group	BEFREE
C0001430	Adenoma	group	BEFREE;LHGDN
C0001618	Tumors of Adrenal Cortex	group	BEFREE
C0001624	Adrenal Gland Neoplasms	group	BEFREE
C0001815	Primary Myelofibrosis	disease	BEFREE
C0002395	Alzheimer's Disease	disease	BEFREE;CTD_human;RGD
C0002726	Amyloidosis	disease	BEFREE
C0002793	Anaplasia	disease	BEFREE
C0002871	Anemia	disease	CTD_human
C0002893	Refractory anemias	disease	BEFREE
C0002991	Cutaneous Fibrous Histiocytoma	disease	BEFREE
C0003467	Anxiety	disease	BEFREE
C0003469	Anxiety Disorders	group	BEFREE
C0003507	Aortic Valve Stenosis	disease	BEFREE
C0003850	Arteriosclerosis	disease	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE;LHGDN
C0004045	Asphyxia Neonatorum	disease	BEFREE
C0004114	Astrocytoma	disease	BEFREE
C0004153	Atherosclerosis	disease	BEFREE;CTD_human;LHGDN
C0004352	Autistic Disorder	group	CTD_human
C0004364	Autoimmune Diseases	group	GWASCAT
C0004763	Barrett Esophagus	disease	BEFREE
C0004903	Beckwith-Wiedemann Syndrome	disease	BEFREE;CTD_human
C0005283	beta Thalassemia	disease	BEFREE
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE
C0005695	Bladder Neoplasm	group	BEFREE;LHGDN
C0005699	Blast Phase	disease	BEFREE
C0005941	Bone Diseases, Developmental	group	CTD_human
C0006118	Brain Neoplasms	group	BEFREE;LHGDN
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0006145	Breast Diseases	group	BEFREE
C0006370	Bulimia	disease	BEFREE
C0006826	Malignant Neoplasms	group	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE;CTD_human
C0007103	Malignant neoplasm of endometrium	disease	BEFREE
C0007115	Malignant neoplasm of thyroid	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE;LHGDN
C0007138	Carcinoma, Transitional Cell	disease	BEFREE
C0007140	Carcinosarcoma	disease	BEFREE
C0007194	Hypertrophic Cardiomyopathy	disease	BEFREE
C0007222	Cardiovascular Diseases	group	BEFREE;HPO
C0007570	Celiac Disease	disease	GWASCAT
C0007847	Malignant tumor of cervix	disease	BEFREE
C0008073	Developmental Disabilities	group	BEFREE
C0008354	Cholera	disease	BEFREE
C0008497	Choriocarcinoma	disease	BEFREE;LHGDN
C0008626	Congenital chromosomal disease	group	BEFREE
C0009241	Cognition Disorders	group	CTD_human
C0009324	Ulcerative Colitis	disease	GWASCAT;LHGDN
C0009375	Colonic Neoplasms	group	BEFREE;CTD_human
C0009402	Colorectal Carcinoma	disease	BEFREE;CTD_human
C0009404	Colorectal Neoplasms	group	BEFREE;CTD_human;LHGDN
C0009447	Common Variable Immunodeficiency	disease	GWASCAT
C0009777	Conn Adenoma	disease	BEFREE
C0010054	Coronary Arteriosclerosis	disease	BEFREE
C0010068	Coronary heart disease	disease	BEFREE
C0010276	Craniopharyngioma	disease	HPO
C0010346	Crohn Disease	disease	GWASCAT
C0010417	Cryptorchidism	disease	HPO
C0010481	Cushing Syndrome	disease	BEFREE
C0010964	Dandy-Walker Syndrome	disease	HPO
C0011265	Presenile dementia	disease	CTD_human
C0011847	Diabetes	disease	BEFREE
C0011849	Diabetes Mellitus	group	BEFREE
C0011854	Diabetes Mellitus, Insulin-Dependent	disease	BEFREE;GWASCAT;GWASDB;MGD;RGD
C0011860	Diabetes Mellitus, Non-Insulin-Dependent	disease	BEFREE;RGD
C0011881	Diabetic Nephropathy	disease	BEFREE
C0012546	Diphtheria	disease	BEFREE
C0013336	Dwarfism	disease	BEFREE
C0013473	Eating Disorders	group	BEFREE
C0013537	Eclampsia	disease	BEFREE
C0014173	Endometrial Hyperplasia	disease	BEFREE
C0014474	Ependymoma	disease	BEFREE
C0014859	Esophageal Neoplasms	group	BEFREE;LHGDN
C0014869	Peptic Esophagitis	disease	BEFREE
C0015300	Exophthalmos	disease	HPO
C0015544	Failure to Thrive	disease	BEFREE
C0015934	Fetal Growth Retardation	phenotype	CTD_human;HPO;LHGDN
C0016034	Breast Fibrocystic Disease	disease	BEFREE
C0016057	Fibrosarcoma	disease	BEFREE
C0016506	Foot Deformities	group	HPO
C0017547	Gigantism	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0018273	Growth Disorders	group	CTD_human
C0018800	Cardiomegaly	phenotype	HPO
C0018801	Heart failure	disease	BEFREE
C0018802	Congestive heart failure	disease	BEFREE
C0018916	Hemangioma	disease	BEFREE;LHGDN
C0018922	hemangiopericytoma	disease	BEFREE
C0019163	Hepatitis B	disease	BEFREE;LHGDN
C0019189	Hepatitis, Chronic	disease	BEFREE
C0019196	Hepatitis C	disease	BEFREE
C0019209	Hepatomegaly	phenotype	HPO
C0019284	Diaphragmatic Hernia	phenotype	CTD_human
C0020217	Hydatidiform Mole	disease	BEFREE
C0020224	Polyhydramnios	phenotype	CTD_human
C0020456	Hyperglycemia	disease	BEFREE
C0020459	Hyperinsulinism	disease	BEFREE
C0020538	Hypertensive disease	group	BEFREE
C0020615	Hypoglycemia	disease	BEFREE;CTD_human
C0021296	Infant, Small for Gestational Age	phenotype	HPO
C0021364	Male infertility	disease	BEFREE
C0021390	Inflammatory Bowel Diseases	group	RGD
C0021670	insulinoma	disease	BEFREE
C0021841	Intestinal Neoplasms	group	BEFREE
C0022134	Islet Cell Adenoma	disease	BEFREE
C0022665	Kidney Neoplasm	disease	BEFREE
C0022739	Klippel-Trenaunay-Weber Syndrome	disease	BEFREE
C0023267	Fibroid Tumor	group	BEFREE
C0023269	leiomyosarcoma	disease	BEFREE
C0023418	leukemia	disease	BEFREE
C0023449	Acute lymphocytic leukemia	disease	BEFREE
C0023452	Childhood Acute Lymphoblastic Leukemia	disease	BEFREE
C0023467	Leukemia, Myelocytic, Acute	disease	BEFREE
C0023470	Myeloid Leukemia	disease	BEFREE
C0023473	Myeloid Leukemia, Chronic	disease	BEFREE
C0023480	Leukemia, Myelomonocytic, Chronic	disease	BEFREE
C0023827	liposarcoma	disease	BEFREE
C0023890	Liver Cirrhosis	disease	BEFREE
C0023895	Liver diseases	group	BEFREE;LHGDN
C0023903	Liver neoplasms	group	BEFREE;CTD_human
C0024032	Low Birth Weights	phenotype	HPO
C0024121	Lung Neoplasms	group	BEFREE
C0024141	Lupus Erythematosus, Systemic	disease	GWASCAT
C0024299	Lymphoma	group	BEFREE
C0024312	Lymphopenia	disease	BEFREE
C0024421	Macroglossia	disease	HPO
C0024530	Malaria	disease	BEFREE
C0024586	Malignant Carcinoid Syndrome	disease	BEFREE
C0024620	Primary Malignant Liver Neoplasm	disease	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0025149	Medulloblastoma	disease	BEFREE
C0025202	melanoma	disease	BEFREE;LHGDN
C0025261	Memory Disorders	disease	CTD_human
C0025286	Meningioma	disease	BEFREE
C0025517	Metabolic Diseases	group	BEFREE
C0025990	Micrognathism	disease	HPO
C0026106	Mild Mental Retardation	disease	HPO
C0026277	Mixed Salivary Gland Tumor	disease	BEFREE
C0026640	Mouth Neoplasms	group	LHGDN
C0026769	Multiple Sclerosis	disease	GWASDB
C0027051	Myocardial Infarction	disease	BEFREE
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0027651	Neoplasms	group	BEFREE
C0027654	Embryonal Neoplasm	disease	BEFREE
C0027658	Neoplasms, Germ Cell and Embryonal	group	LHGDN
C0027708	Nephroblastoma	disease	BEFREE;CTD_human;HPO
C0027709	Nephrocalcinosis	disease	HPO
C0027746	Nerve Degeneration	phenotype	CTD_human
C0027773	Nesidioblastosis	disease	BEFREE
C0027794	Neural Tube Defects	group	BEFREE
C0027819	Neuroblastoma	group	BEFREE
C0027962	Melanocytic nevus	disease	BEFREE;HPO
C0028754	Obesity	disease	BEFREE;CTD_human
C0028960	Oligospermia	disease	BEFREE
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029456	Osteoporosis	disease	RGD
C0029463	Osteosarcoma	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030567	Parkinson Disease	disease	BEFREE;CTD_human;LHGDN
C0031511	Pheochromocytoma	disease	BEFREE
C0032000	Pituitary Adenoma	disease	BEFREE
C0032002	Pituitary Diseases	group	BEFREE
C0032045	Placenta Disorders	group	CTD_human
C0032460	Polycystic Ovary Syndrome	disease	BEFREE
C0032463	Polycythemia Vera	disease	BEFREE
C0032580	Adenomatous Polyposis Coli	disease	BEFREE
C0032914	Pre-Eclampsia	phenotype	LHGDN
C0032927	Precancerous Conditions	group	BEFREE;CTD_human
C0032969	Pregnancy in Diabetics	phenotype	BEFREE
C0033578	Prostatic Neoplasms	group	BEFREE;LHGDN
C0033860	Psoriasis	disease	GWASCAT
C0034069	Pulmonary Fibrosis	disease	LHGDN
C0035372	Rett Syndrome	disease	BEFREE
C0035412	Rhabdomyosarcoma	disease	BEFREE;CTD_human
C0035439	Rheumatic Heart Disease	disease	BEFREE
C0036095	Salivary Gland Neoplasms	group	BEFREE
C0036341	Schizophrenia	disease	BEFREE;PSYGENET
C0036631	Seminoma	disease	BEFREE;HPO
C0037579	Soft Tissue Neoplasms	group	BEFREE
C0037932	Curvature of spine	phenotype	HPO
C0038013	Ankylosing spondylitis	disease	GWASCAT
C0038356	Stomach Neoplasms	group	BEFREE
C0039075	Syndactyly	disease	HPO
C0039101	synovial sarcoma	disease	BEFREE
C0039590	Testicular Neoplasms	group	BEFREE
C0040028	Thrombocythemia, Essential	disease	BEFREE
C0040136	Thyroid Neoplasm	disease	BEFREE
C0041107	Trisomy	group	BEFREE
C0041408	Turner Syndrome	disease	BEFREE
C0041667	Underweight	phenotype	HPO
C0042133	Uterine Fibroids	group	BEFREE
C0042580	Vesico-Ureteral Reflux	disease	HPO
C0043119	Werner Syndrome	disease	BEFREE
C0079588	Ichthyosis, X-Linked	disease	BEFREE
C0085083	Ovarian Hyperstimulation Syndrome	disease	BEFREE
C0085281	Addictive Behavior	phenotype	BEFREE
C0085653	Pyogenic granuloma	disease	BEFREE
C0085677	Alcoholic Neuropathy	disease	RGD
C0086648	MPS III B	disease	BEFREE
C0087031	Juvenile-Onset Still Disease	disease	GWASCAT
C0149519	Chronic Persistent Hepatitis	disease	BEFREE
C0149721	Left Ventricular Hypertrophy	disease	BEFREE
C0151546	Oral Cavity Carcinoma	disease	BEFREE
C0151744	Myocardial Ischemia	disease	BEFREE
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0152018	Esophageal carcinoma	disease	BEFREE
C0153381	Malignant neoplasm of mouth	disease	BEFREE
C0153658	Malignant neoplasm of endocrine gland	disease	BEFREE
C0158986	Neonatal hypoglycemia	disease	HPO
C0175693	Russell-Silver syndrome	disease	BEFREE;CLINVAR;CTD_human;GENOMICS_ENGLAND;ORPHANET
C0175754	Agenesis of corpus callosum	disease	BEFREE
C0178468	Autoimmune thyroid disease	disease	GWASCAT
C0178874	Tumor Progression	phenotype	BEFREE
C0205851	Germ cell tumor	group	BEFREE
C0206081	Hyperandrogenism	disease	BEFREE
C0206093	Neuroectodermal Tumors	disease	BEFREE
C0206624	Hepatoblastoma	disease	BEFREE;CTD_human;HPO;LHGDN
C0206628	Mesoblastic Nephroma	disease	LHGDN
C0206651	Clear Cell Sarcoma of Soft Tissue	disease	BEFREE;LHGDN
C0206655	Alveolar rhabdomyosarcoma	disease	BEFREE
C0206656	Embryonal Rhabdomyosarcoma	disease	BEFREE
C0206658	Smooth Muscle Tumor	disease	BEFREE
C0206661	Gonadoblastoma	disease	HPO
C0206667	Adrenal Cortical Adenoma	disease	BEFREE
C0206677	Adenomatous Polyps	disease	BEFREE
C0206686	Adrenocortical carcinoma	disease	BEFREE;CTD_human;HPO;LHGDN
C0206731	Angiofibroma	disease	LHGDN
C0206733	Strawberry nevus of skin	disease	BEFREE
C0206743	Rhabdoid Tumor	disease	BEFREE
C0206754	Neuroendocrine Tumors	group	BEFREE
C0220620	Gastrointestinal Carcinoid Tumor	disease	BEFREE
C0220641	Lip and Oral Cavity Carcinoma	disease	BEFREE
C0221263	Cafe-au-Lait Spots	phenotype	HPO
C0221354	Frontal bossing	disease	HPO
C0221766	Diastasis recti	phenotype	HPO
C0231230	Fatigability	phenotype	BEFREE
C0231528	Myalgia	phenotype	BEFREE
C0233794	Memory impairment	phenotype	CTD_human
C0234233	Sore to touch	phenotype	BEFREE
C0235752	Port-Wine Stain	disease	HPO
C0235974	Pancreatic carcinoma	disease	BEFREE
C0235991	Small for gestational age (disorder)	phenotype	HPO
C0238198	Gastrointestinal Stromal Tumors	group	BEFREE
C0238506	Congenital posterior urethral valves	disease	HPO
C0239234	Low set ears	phenotype	HPO
C0242363	Islet Cell Tumor	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0243050	Cardiovascular Abnormalities	group	HPO
C0262444	Abnormality of the dentition	phenotype	HPO
C0265554	Ectrodactyly	disease	BEFREE
C0265974	Birthmark	phenotype	HPO
C0271561	Somatotropin deficiency	disease	BEFREE
C0271708	Fasting Hypoglycemia	phenotype	BEFREE;CTD_human;HPO
C0271710	Reactive hypoglycemia	disease	CTD_human
C0276496	Familial Alzheimer Disease (FAD)	disease	CTD_human
C0277828	Late fontanel closure	phenotype	HPO
C0278701	Gastric Adenocarcinoma	disease	BEFREE
C0278996	Malignant Head and Neck Neoplasm	disease	BEFREE
C0279000	Liver and Intrahepatic Biliary Tract Carcinoma	disease	BEFREE
C0279607	Adult Hepatocellular Carcinoma	disease	RGD
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0280324	Laryngeal Squamous Cell Carcinoma	disease	BEFREE
C0280631	Leiomyosarcoma of uterus	disease	BEFREE
C0281784	Benign Meningioma	disease	BEFREE
C0282160	Aplasia Cutis Congenita	disease	BEFREE
C0282313	Condition, Preneoplastic	phenotype	CTD_human
C0282606	Myomatous neoplasm	disease	BEFREE
C0282612	Prostatic Intraepithelial Neoplasias	disease	BEFREE
C0302592	Cervix carcinoma	disease	BEFREE
C0332890	Congenital hemihypertrophy	disease	HPO;ORPHANET
C0333463	Senile Plaques	phenotype	BEFREE
C0334463	Malignant Fibrous Histiocytoma	disease	BEFREE
C0334488	Clear cell sarcoma of kidney	disease	BEFREE
C0334492	Malignant mesenchymal tumor	disease	BEFREE
C0334634	Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse	disease	BEFREE
C0338106	Adenocarcinoma of colon	disease	BEFREE
C0338656	Impaired cognition	disease	BEFREE
C0340288	Stable angina	disease	BEFREE
C0341439	Chronic liver disease	group	BEFREE
C0342326	Tumor-induced hypoglycemia	disease	BEFREE
C0342443	Adrenal Cushing's syndrome	disease	BEFREE
C0342494	Adrenocortical hyperplasia	disease	BEFREE
C0345904	Malignant neoplasm of liver	disease	BEFREE;CTD_human
C0345967	Malignant mesothelioma	disease	BEFREE
C0346402	Malignant neoplasm of adrenal cortex	disease	BEFREE
C0346429	Multiple malignancy	phenotype	BEFREE
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0349588	Short stature	phenotype	HPO
C0349604	Intracranial Meningioma	disease	BEFREE
C0349622	Hemangiopericytoma of meninges	disease	BEFREE
C0349782	Ischemic cardiomyopathy	disease	BEFREE
C0375023	Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0392525	Nephrolithiasis	disease	HPO
C0393706	Early infantile epileptic encephalopathy with suppression bursts	disease	BEFREE
C0403824	Teratozoospermia	disease	BEFREE
C0410158	Muscle damage	phenotype	BEFREE
C0424295	Hyperactive behavior	phenotype	BEFREE
C0432072	Dysmorphic features	disease	BEFREE
C0432365	Thalidomide embryopathy syndrome	disease	BEFREE
C0432409	Trisomy 11	disease	BEFREE
C0456132	Large fontanelle	phenotype	HPO
C0476089	Endometrial Carcinoma	disease	BEFREE
C0494165	Secondary malignant neoplasm of liver	disease	BEFREE
C0494463	Alzheimer Disease, Late Onset	disease	CTD_human
C0496870	Benign neoplasm of liver	disease	BEFREE
C0497406	Overweight	phenotype	BEFREE
C0520463	Chronic active hepatitis	disease	BEFREE
C0524620	Metabolic Syndrome X	disease	BEFREE;RGD
C0541764	Delayed bone age	phenotype	HPO
C0542514	Blue sclera	phenotype	HPO
C0542518	Enlarged kidney	phenotype	HPO
C0545053	Advanced bone age	phenotype	HPO
C0546126	Acute Confusional Senile Dementia	disease	CTD_human
C0546837	Malignant neoplasm of esophagus	disease	BEFREE
C0549473	Thyroid carcinoma	disease	BEFREE
C0553580	Ewings sarcoma	disease	BEFREE
C0557874	Global developmental delay	disease	HPO
C0576962	Tooth problem	phenotype	HPO
C0585442	Osteosarcoma of bone	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0598766	Leukemogenesis	disease	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677659	Gastro-esophageal reflux disease with esophagitis	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0678213	Complete hydatidiform mole	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0678807	prenatal alcohol exposure	phenotype	PSYGENET
C0684249	Carcinoma of lung	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0700095	Central neuroblastoma	disease	BEFREE
C0700208	Acquired scoliosis	phenotype	HPO
C0750887	Adrenal Cancer	disease	BEFREE
C0750900	Alzheimer's Disease, Focal Onset	disease	CTD_human
C0750901	Alzheimer Disease, Early Onset	disease	CTD_human
C0751292	Age-Related Memory Disorders	disease	CTD_human
C0751293	Memory Disorder, Semantic	disease	CTD_human
C0751294	Memory Disorder, Spatial	disease	CTD_human
C0751295	Memory Loss	phenotype	CTD_human
C0751364	Cancer, Embryonal	phenotype	BEFREE
C0751955	Brain Infarction	disease	RGD
C0752347	Lewy Body Disease	disease	BEFREE;CTD_human
C0795690	Congenital omphalocele	disease	BEFREE;HPO
C0796154	SIMPSON-GOLABI-BEHMEL SYNDROME, TYPE 1	disease	BEFREE
C0796160	MENTAL RETARDATION, X-LINKED, SNYDER-ROBINSON TYPE	disease	BEFREE
C0848558	Hypospadias	group	HPO
C0850639	premalignant lesion	phenotype	BEFREE
C0853879	Invasive carcinoma of breast	disease	BEFREE
C0854917	Rhabdoid Tumor of the Kidney	disease	BEFREE
C0855228	Eating disorder symptom	phenotype	BEFREE
C0878544	Cardiomyopathies	group	HPO
C0878787	Growth failure	phenotype	BEFREE
C0919267	ovarian neoplasm	disease	BEFREE;LHGDN
C0936016	Testicular Feminization	disease	BEFREE
C0940937	precancerous lesions	phenotype	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1153706	Endometrial adenocarcinoma	disease	BEFREE
C1258085	Barrett Epithelium	disease	BEFREE
C1261473	Sarcoma	group	BEFREE
C1262091	Lymphocytic infiltration	disease	BEFREE
C1262477	Weight decreased	phenotype	HPO
C1266119	Solitary fibrous tumor	disease	BEFREE
C1275122	Familial multiple trichoepitheliomata	disease	BEFREE
C1275417	Non-involuting congenital hemangioma	disease	BEFREE
C1275421	Rapidly involuting congenital hemangioma	disease	BEFREE
C1292778	Chronic myeloproliferative disorder	disease	BEFREE
C1302401	Adenoma of large intestine	disease	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1306503	Congenital exomphalos	disease	BEFREE
C1306710	Facial asymmetry	phenotype	HPO
C1319016	Nephrogenic rest, intralobar	disease	BEFREE
C1319017	Nephrogenic rest, perilobar	phenotype	BEFREE
C1320468	Nephrogenic rest	phenotype	BEFREE
C1332965	Congenital Mesoblastic Nephroma	disease	BEFREE
C1333990	Hereditary Nonpolyposis Colorectal Cancer	disease	BEFREE
C1334620	Malignant Smooth Muscle Neoplasm	disease	BEFREE
C1335302	Pancreatic Ductal Adenocarcinoma	disease	BEFREE
C1337011	Well Differentiated Pancreatic Endocrine Tumor	disease	BEFREE
C1384514	Conn Syndrome	disease	BEFREE
C1386048	Intrauterine retardation	phenotype	HPO
C1395512	Placental dysfunction	disease	BEFREE
C1402315	Vascular lesions	disease	BEFREE
C1458155	Mammary Neoplasms	group	BEFREE;LHGDN
C1509147	Histiocytoma	disease	BEFREE
C1512409	Hepatocarcinogenesis	disease	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE;CTD_human
C1527390	Neoplasms, Intracranial	group	BEFREE
C1561826	Overweight and obesity	disease	BEFREE
C1563937	Atherogenesis	phenotype	CTD_human
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1623038	Cirrhosis	disease	BEFREE
C1691215	Penile hypospadias	disease	HPO
C1704272	Benign Prostatic Hyperplasia	disease	BEFREE
C1704374	Carcinoma of Endocrine Gland	disease	BEFREE
C1737329	Dysmorphism	disease	BEFREE
C1762616	Meningioma, benign, no ICD-O subtype	disease	BEFREE
C1834060	Short middle phalanx of the 5th finger	phenotype	HPO
C1834167	Asymmetric overgrowth	phenotype	HPO
C1835884	Triangular face	phenotype	HPO
C1836674	Short distal phalanx of the 5th finger	phenotype	HPO
C1837260	Prominent forehead	phenotype	HPO
C1837760	Prominent eyes	phenotype	HPO
C1840382	Abnormality of the ureter	phenotype	HPO
C1844806	Weight less than 3rd percentile	phenotype	HPO
C1845847	Coarse facial features	phenotype	HPO
C1848490	Protruding eyes	phenotype	HPO
C1849075	Relative macrocephaly	disease	HPO
C1849157	Resistance to Insulin-Like Growth Factor I	disease	BEFREE
C1849265	Overgrowth	phenotype	HPO
C1850049	Clinodactyly of the 5th finger	disease	HPO
C1851720	Adrenocortical cytomegaly	phenotype	HPO
C1851722	Overgrowth of external genitalia	phenotype	HPO
C1851731	Generalized overgrowth	phenotype	HPO
C1851733	Pancreatic hyperplasia	phenotype	HPO
C1852092	DIABETES MELLITUS, INSULIN-DEPENDENT, 2	disease	MGD
C1853242	Midface retrusion	phenotype	HPO
C1853737	Prominent occiput	phenotype	HPO
C1854301	Motor delay	phenotype	HPO
C1856184	HEMIHYPERPLASIA, ISOLATED	disease	ORPHANET
C1857130	Hypoplastic mandible condyle	phenotype	HPO
C1857276	Trichohepatoenteric Syndrome	disease	BEFREE
C1857949	Prominent metopic ridge	phenotype	HPO
C1858033	Asymmetry of the thorax	phenotype	HPO
C1858120	Generalized hypotonia	phenotype	HPO
C1861305	TARSAL-CARPAL COALITION SYNDROME	disease	BEFREE
C1862140	Brachydactyly type A3	disease	HPO
C1862425	Prominent globes	phenotype	HPO
C1862761	Increased hepatocellular carcinoma risk	phenotype	HPO
C1864897	Cognitive delay	phenotype	HPO
C1866195	Downturned corners of mouth	phenotype	HPO
C1867114	Craniofacial disproportion	phenotype	HPO
C1867446	Bulging forehead	phenotype	HPO
C1867955	Increased incidence of hepatocellular carcinoma	phenotype	HPO
C1883486	Uterine Corpus Cancer	disease	BEFREE
C1956089	Osteophyte	disease	BEFREE
C1956346	Coronary Artery Disease	disease	BEFREE
C1961102	Precursor Cell Lymphoblastic Leukemia Lymphoma	disease	BEFREE
C1969144	Renal cortical cysts	phenotype	HPO
C2145472	Urothelial Carcinoma	disease	BEFREE
C2239176	Liver carcinoma	disease	BEFREE;CTD_human;HPO;LHGDN
C2267227	Bulimia Nervosa	disease	BEFREE
C2362324	Pediatric Obesity	disease	BEFREE
C2673410	Small midface	phenotype	HPO
C2674608	Feeding difficulties in infancy	phenotype	HPO
C2699510	Split-Hand/Foot Malformation	disease	BEFREE
C2711227	Steatohepatitis	disease	BEFREE
C2717836	Steroid Sulfatase Deficiency Disease	disease	BEFREE
C2930471	Bilateral Wilms Tumor	disease	CTD_human
C2931019	Split hand foot deformity 1	disease	BEFREE
C2931618	Gestational trophoblastic disease	disease	BEFREE
C2936904	Opitz GBBB Syndrome, X-Linked	disease	BEFREE
C2937421	Prostatic Hyperplasia	disease	BEFREE
C2986703	Overgrowth Syndrome	disease	BEFREE
C3150281	Fetal overgrowth	phenotype	HPO
C3463897	HYDATIDIFORM MOLE, RECURRENT, 1	disease	BEFREE
C3495559	Juvenile arthritis	disease	GWASCAT
C3539878	Triple Negative Breast Neoplasms	disease	BEFREE
C3539909	Allergic disposition	phenotype	BEFREE
C3714514	Infection	group	LHGDN
C3714756	Intellectual Disability	group	GENOMICS_ENGLAND
C3714758	Juvenile psoriatic arthritis	disease	GWASCAT
C3714796	Isolated somatotropin deficiency	disease	HPO
C3714948	PACHYONYCHIA CONGENITA 3	disease	BEFREE
C3813158	Experimental Organism Islet Cell Adenoma Neoplasm	phenotype	BEFREE
C3837958	Diabetes Mellitus, Ketosis-Prone	disease	MGD
C3841475	beta^+^ Thalassemia	disease	BEFREE
C3887461	Head and Neck Carcinoma	disease	BEFREE
C4020874	No development of motor milestones	phenotype	HPO
C4020875	Mental and motor retardation	phenotype	HPO
C4021539	Posterior helix pit	phenotype	HPO
C4021790	Abnormality of the skeletal system	phenotype	BEFREE
C4024589	Aplasia/Hypoplasia of the mandible	phenotype	HPO
C4048328	cervical cancer	disease	BEFREE
C4054122	Rat Adrenal Gland Pheochromocytoma	disease	BEFREE
C4054726	Infant Leukemia	disease	BEFREE
C4072820	Large bregma sutures	phenotype	HPO
C4072821	Large, late-closing fontanelle	phenotype	HPO
C4072822	Wide bregma sutures	phenotype	HPO
C4072825	Thickened facial skin with coarse facial features	phenotype	HPO
C4086165	Childhood Neuroblastoma	disease	BEFREE
C4225307	GROWTH RESTRICTION, SEVERE, WITH DISTINCTIVE FACIES	disease	CLINVAR;CTD_human
C4237343	Overweight or obesity	phenotype	BEFREE
C4280269	Noncancerous mole	phenotype	HPO
C4280320	Hypotrophic midface	phenotype	HPO
C4280321	Decreased projection of midface	phenotype	HPO
C4280538	Curvature of little finger	phenotype	HPO
C4280652	Prominent back of the head	phenotype	HPO
C4280679	Increased calcium level in kidney	phenotype	HPO
C4290090	diabetes (mellitus) due to autoimmune process	disease	MGD
C4290091	diabetes (mellitus) due to immune mediated pancreatic islet beta-cell destruction	disease	MGD
C4290092	idiopathic diabetes (mellitus)	disease	MGD
C4476523	Decreased projection of lower jaw	phenotype	HPO
C4476524	Decreased projection of mandible	phenotype	HPO
C4476525	Retrusion of lower jaw	phenotype	HPO

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0005158	insulin receptor binding	IPI
GO:0005159	insulin-like growth factor receptor binding	IMP
GO:0005178	integrin binding	IDA
GO:0005179	hormone activity	IEA
GO:0005515	protein binding	IPI
GO:0008083	growth factor activity	IDA
GO:0043539	protein serine/threonine kinase activator activity	ISS
GO:0048018	receptor ligand activity	ISS

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000122	negative regulation of transcription by RNA polymerase II	ISS
GO:0001501	skeletal system development	TAS
GO:0001649	osteoblast differentiation	IEA
GO:0001701	in utero embryonic development	ISS
GO:0001892	embryonic placenta development	ISS
GO:0001934	positive regulation of protein phosphorylation	ISS
GO:0002576	platelet degranulation	TAS
GO:0006006	glucose metabolic process	IEA
GO:0006349	regulation of gene expression by genetic imprinting	TAS
GO:0006355	regulation of transcription, DNA-templated	NAS
GO:0007275	multicellular organism development	TAS
GO:0008284	positive regulation of cell population proliferation	IC
GO:0008284	positive regulation of cell population proliferation	IDA
GO:0008286	insulin receptor signaling pathway	TAS
GO:0009887	animal organ morphogenesis	IEA
GO:0031017	exocrine pancreas development	IEA
GO:0031056	regulation of histone modification	ISS
GO:0038028	insulin receptor signaling pathway via phosphatidylinositol 3-kinase	ISS
GO:0040018	positive regulation of multicellular organism growth	IEA
GO:0042104	positive regulation of activated T cell proliferation	IDA
GO:0043085	positive regulation of catalytic activity	ISS
GO:0043410	positive regulation of MAPK cascade	IDA
GO:0044267	cellular protein metabolic process	TAS
GO:0045725	positive regulation of glycogen biosynthetic process	ISS
GO:0045840	positive regulation of mitotic nuclear division	IDA
GO:0045944	positive regulation of transcription by RNA polymerase II	IEA
GO:0046628	positive regulation of insulin receptor signaling pathway	IDA
GO:0050731	positive regulation of peptidyl-tyrosine phosphorylation	ISS
GO:0051146	striated muscle cell differentiation	IEA
GO:0051147	regulation of muscle cell differentiation	ISS
GO:0051781	positive regulation of cell division	IEA
GO:0051897	positive regulation of protein kinase B signaling	IDA
GO:0060669	embryonic placenta morphogenesis	ISS
GO:0060720	spongiotrophoblast cell proliferation	IEA
GO:0071902	positive regulation of protein serine/threonine kinase activity	IEA
GO:2000467	positive regulation of glycogen (starch) synthase activity	ISS

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005576	extracellular region	TAS
GO:0005615	extracellular space	IEA
GO:0031093	platelet alpha granule lumen	TAS

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-114608	Platelet degranulation	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	TAS
R-HSA-2428924	IGF1R signaling cascade	TAS
R-HSA-2428928	IRS-related events triggered by IGF1R	TAS
R-HSA-2428933	SHC-related events triggered by IGF1R	TAS
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-76002	Platelet activation, signaling and aggregation	TAS
R-HSA-76005	Response to elevated platelet cytosolic Ca2+	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C026486	1,2,5,6-dibenzanthracene	[Benzo(a)pyrene co-treated with 1,2,5,6-dibenzanthracene] affects the expression of IGF2 mRNA	17690111
C031763	1,3-butadiene	1,3-butadiene results in decreased expression of IGF2 mRNA	29038090
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of IGF2 mRNA	28628672
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of IGF2 mRNA	28628672
D015056	1-Methyl-3-isobutylxanthine	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of IGF2 mRNA	28628672
D015058	1-Naphthylisothiocyanate	1-Naphthylisothiocyanate results in decreased expression of IGF2 mRNA	30723492
C511295	2,2',4,4'-tetrabromodiphenyl ether	2,2',4,4'-tetrabromodiphenyl ether results in increased expression of IGF2 mRNA	21394737
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]	24055520
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased susceptibility to IGF2 protein	24055520
C085911	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]]	23419388
D015073	2-Acetylaminofluorene	2-Acetylaminofluorene results in increased expression of IGF2 mRNA	22213190
C021296	2-ethoxyethanol	2-ethoxyethanol results in increased expression of IGF2 mRNA	19643169
C434003	3-(4-methylphenylsulfonyl)-2-propenenitrile	3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]	24055520
C434003	3-(4-methylphenylsulfonyl)-2-propenenitrile	3-(4-methylphenylsulfonyl)-2-propenenitrile results in decreased susceptibility to IGF2 protein	24055520
C009505	4,4'-diaminodiphenylmethane	4,4'-diaminodiphenylmethane affects the expression of IGF2 mRNA	18648102
C002202	4-oxoretinoic acid	4-oxoretinoic acid results in decreased expression of IGF2 mRNA	15982314
C000595015	6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine results in decreased expression of IGF2 mRNA	28073004
C000601052	(6,7-dimethoxyquinolin-4-yl)(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl acetate	(6,7-dimethoxyquinolin-4-yl)(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl acetate results in decreased expression of IGF2 mRNA	25976766
C000601052	(6,7-dimethoxyquinolin-4-yl)(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl acetate	(6,7-dimethoxyquinolin-4-yl)(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)methyl acetate results in decreased expression of IGF2 protein	25976766
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of IGF2 mRNA	20382639
D015127	9,10-Dimethyl-1,2-benzanthracene	9,10-Dimethyl-1,2-benzanthracene results in decreased expression of IGF2 mRNA	19480007
D000082	Acetaminophen	Acetaminophen results in decreased expression of IGF2 mRNA	26690555
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of IGF2 intron	30157460
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of IGF2 mRNA	20036727
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of IGF2 protein	20036727
D000447	Aldehydes	Aldehydes results in increased expression of IGF2 mRNA	25014914
C011512	alpha-naphthoflavone	alpha-naphthoflavone inhibits the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to IGF2 promoter]]	29094188
C011512	alpha-naphthoflavone	alpha-naphthoflavone inhibits the reaction [Methylcholanthrene results in increased acetylation of IGF2 promoter]	29094188
C011512	alpha-naphthoflavone	alpha-naphthoflavone inhibits the reaction [Methylcholanthrene results in increased expression of IGF2 mRNA]	29094188
C011512	alpha-naphthoflavone	alpha-naphthoflavone inhibits the reaction [Methylcholanthrene results in increased methylation of IGF2 promoter]	29094188
C011512	alpha-naphthoflavone	alpha-naphthoflavone results in decreased acetylation of IGF2 promoter	29094188
C032311	aluminum fluoride	aluminum fluoride results in increased expression of IGF2 mRNA	11996908
C032311	aluminum fluoride	aluminum fluoride results in increased expression of IGF2 protein	11996908
C041524	aluminum sulfate	aluminum sulfate results in increased secretion of IGF2 mRNA	7685579
C041524	aluminum sulfate	aluminum sulfate results in increased secretion of IGF2 protein	7685579
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of IGF2 mRNA	16483693
D018501	Antirheumatic Agents	Antirheumatic Agents results in increased expression of IGF2 mRNA	24449571
D000077237	Arsenic Trioxide	[Arsenic Trioxide co-treated with Curcumin] results in increased expression of IGF2 protein	27430728
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of IGF2 mRNA	25258189
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of IGF2 protein	27430728
D017638	Asbestos, Crocidolite	Asbestos, Crocidolite results in increased expression of IGF2 mRNA	24160326
D017632	Asbestos, Serpentine	Asbestos, Serpentine results in increased expression of IGF2 mRNA	24160326
D001241	Aspirin	Aspirin results in decreased expression of IGF2 mRNA	9399670
D001280	Atrazine	Atrazine results in decreased expression of IGF2 mRNA	27413107
C547126	AZM551248	AZM551248 results in decreased expression of IGF2 mRNA	22323515
D001562	Benzimidazoles	Benzimidazoles inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]	24055520
D001562	Benzimidazoles	Benzimidazoles results in decreased susceptibility to IGF2 protein	24055520
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with 1,2,5,6-dibenzanthracene] affects the expression of IGF2 mRNA	17690111
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with benzo(b)fluoranthene] affects the expression of IGF2 mRNA	17690111
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of IGF2 mRNA	26238291
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of IGF2 mRNA	22316170
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of IGF2 mRNA	22228805
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of IGF2 mRNA	22342234
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of IGF2 mRNA	21839799
C006703	benzo(b)fluoranthene	[Benzo(a)pyrene co-treated with benzo(b)fluoranthene] affects the expression of IGF2 mRNA	17690111
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]	24055520
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [IGF2 protein results in increased expression of STS protein]	24055520
C072553	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased susceptibility to IGF2 protein	24055520
D000077610	Bexarotene	Bexarotene results in increased expression of IGF2 mRNA	16648578
C543008	bis(4-hydroxyphenyl)sulfone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of IGF2 mRNA	28628672
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in increased expression of IGF2 mRNA	30951980
C006780	bisphenol A	bisphenol A affects the expression of IGF2 mRNA	30903817
C006780	bisphenol A	bisphenol A results in decreased expression of IGF2 mRNA	27685785
C006780	bisphenol A	bisphenol A results in decreased methylation of IGF2 gene	29513082
C006780	bisphenol A	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of IGF2 mRNA	28628672
C006780	bisphenol A	bisphenol A affects the methylation of IGF2 promoter	23593014
C006780	bisphenol A	bisphenol A results in decreased methylation of IGF2 promoter	27312807
C006780	bisphenol A	bisphenol A results in increased expression of IGF2 mRNA	23593014; 25807043; 29161229; 30951980;
C006780	bisphenol A	bisphenol A results in increased methylation of IGF2 gene	25807043
C006780	bisphenol A	bisphenol A results in increased methylation of IGF2 promoter	29161229
C006780	bisphenol A	bisphenol A results in decreased expression of IGF2 mRNA	20505776
C006780	bisphenol A	bisphenol A results in increased expression of IGF2 mRNA	29635046
C006780	bisphenol A	bisphenol A affects the expression of IGF2 mRNA	25181051
C006780	bisphenol A	bisphenol A results in decreased expression of IGF2 mRNA	23653003; 30816183;
C000611646	bisphenol F	[bisphenol F co-treated with Tretinoin] results in decreased expression of IGF2 mRNA	30951980
C000611646	bisphenol F	bisphenol F results in increased expression of IGF2 mRNA	30951980
D000069286	Bortezomib	Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]	24055520
D000069286	Bortezomib	Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein]	24055520
D000069286	Bortezomib	Bortezomib results in decreased susceptibility to IGF2 protein	24055520
D019819	Budesonide	Budesonide inhibits the reaction [vinyl carbamate results in decreased methylation of IGF2 protein]	15824018
C018475	butyraldehyde	butyraldehyde results in increased expression of IGF2 mRNA	26079696
D002104	Cadmium	Cadmium promotes the reaction [IGF2 protein binds to IGF1R protein]	9648927
D002104	Cadmium	Cadmium results in increased expression of IGF2 mRNA	31082426
D002104	Cadmium	Cadmium results in decreased expression of IGF2 mRNA	24067728
D002110	Caffeine	Caffeine results in decreased expression of IGF2 mRNA	26179615
D002118	Calcium	Cobalt inhibits the reaction [IGF2 protein results in increased import of Calcium]	2442157; 2539779;
D002118	Calcium	[IGF2 protein co-treated with EGF protein] results in increased import of Calcium	2442157
D002118	Calcium	IGF2 protein results in increased import of Calcium	2442157; 2460452; 2539779;
D002118	Calcium	Lanthanum inhibits the reaction [IGF2 protein results in increased import of Calcium]	2442157
D002118	Calcium	Pertussis Toxin inhibits the reaction [IGF2 protein results in increased import of Calcium]	2442157
D002118	Calcium	tetramethrin inhibits the reaction [IGF2 protein results in increased import of Calcium]	2442157; 2539779;
D002211	Capsaicin	Capsaicin results in increased expression of IGF2 mRNA	20349343
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of IGF2 mRNA	11566570
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of IGF2 mRNA	17032414
C010063	carbonyl sulfide	carbonyl sulfide results in decreased expression of IGF2 mRNA	19395590
D002330	Carmustine	IGF2 mRNA affects the susceptibility to Carmustine	16365179
D002762	Cholecalciferol	Cholecalciferol results in increased expression of IGF2 mRNA	17170073
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of IGF2 mRNA	20938992
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of IGF2 gene	20938992
D002794	Choline	Choline results in increased expression of IGF2 mRNA	17264169
D002794	Choline	Choline results in increased expression of IGF2 protein	17264169
D002857	Chromium	Chromium deficiency results in decreased expression of IGF2 protein	9868179
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in increased expression of IGF2 mRNA	27392435
D002945	Cisplatin	Cisplatin results in increased expression of IGF2 mRNA	27392435
D002994	Clofibrate	Clofibrate results in decreased expression of IGF2 mRNA	16081524
D003035	Cobalt	Cobalt inhibits the reaction [IGF2 protein results in increased import of Calcium]	2442157; 2539779;
C018021	cobaltous chloride	cobaltous chloride results in increased expression of IGF2 mRNA	25100165
C018021	cobaltous chloride	HIF1A mutant form inhibits the reaction [cobaltous chloride results in increased expression of IGF2 mRNA]	25100165
C018021	cobaltous chloride	cobaltous chloride results in decreased expression of IGF2 mRNA	21167956
D003042	Cocaine	Cocaine results in decreased expression of IGF2 mRNA	16076954
D003345	Corticosterone	IGF2 protein inhibits the reaction [Corticosterone results in decreased expression of SOD2 protein]	24667322
D003345	Corticosterone	[IGF2R protein co-treated with IGF1R protein] affects the reaction [IGF2 protein inhibits the reaction [Corticosterone results in decreased expression of SOD2 protein]]	24667322
C030973	cupric oxide	cupric oxide results in increased expression of IGF2 mRNA	22077320
D003471	Cuprizone	Cuprizone results in increased expression of IGF2 mRNA	26577399
D003474	Curcumin	[Arsenic Trioxide co-treated with Curcumin] results in increased expression of IGF2 protein	27430728
D003474	Curcumin	Curcumin analog results in decreased expression of IGF2 mRNA	26409325
C028972	dan-shen root extract	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]]	23419388
C028972	dan-shen root extract	dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in decreased expression of BAD protein modified form]	23419388
C028972	dan-shen root extract	dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased activity of IGF2R protein]	23419388
C028972	dan-shen root extract	dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]	23419388
C028972	dan-shen root extract	dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of BAD protein]	23419388
C028972	dan-shen root extract	dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of BCL2L1 protein]	23419388
C028972	dan-shen root extract	dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of CYCS protein]	23419388
C028972	dan-shen root extract	dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of GNAQ protein]	23419388
C028972	dan-shen root extract	dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of IGF2R protein]	23419388
C028972	dan-shen root extract	dan-shen root extract results in decreased susceptibility to IGF2 protein mutant form	23419388
C028972	dan-shen root extract	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in decreased expression of BAD protein modified form]]	23419388
C028972	dan-shen root extract	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]]	23419388
C028972	dan-shen root extract	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of BCL2L1 protein]]	23419388
C028972	dan-shen root extract	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of GNAQ protein]]	23419388
C028972	dan-shen root extract	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of IGF2R protein]]	23419388
C028972	dan-shen root extract	Fulvestrant inhibits the reaction [dan-shen root extract results in decreased susceptibility to IGF2 protein mutant form]	23419388
D003620	Dantrolene	Dantrolene results in decreased susceptibility to IGF2 protein	16485066
D000069439	Dasatinib	Dasatinib results in increased expression of IGF2 mRNA	20579391
D003634	DDT	DDT results in decreased expression of IGF2 mRNA	19797855
C017180	decamethrin	decamethrin results in decreased expression of IGF2 mRNA	20647053
D000077209	Decitabine	Decitabine inhibits the reaction [tobacco tar results in decreased expression of IGF2 mRNA]	19559774
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of IGF2 mRNA	28628672
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of IGF2 mRNA	28628672
D003907	Dexamethasone	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of IGF2 mRNA	28628672
D003907	Dexamethasone	Dexamethasone results in increased expression of IGF2 mRNA	22733784
D003907	Dexamethasone	Dexamethasone inhibits the reaction [nitrofen results in increased expression of IGF2 mRNA]	10370016
D003907	Dexamethasone	Dexamethasone inhibits the reaction [nitrofen results in increased expression of IGF2 protein]	10370016
D003976	Diazinon	Diazinon affects the expression of IGF2 mRNA	22546817
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in increased expression of IGF2 mRNA	15829613; 21266533;
D003999	Dichloroacetic Acid	Dichloroacetic Acid results in decreased expression of IGF2 mRNA	28962523
D003999	Dichloroacetic Acid	Dichloroacetic Acid results in decreased methylation of IGF2 gene	15036762
D003633	Dichlorodiphenyl Dichloroethylene	Dichlorodiphenyl Dichloroethylene results in decreased expression of IGF2 mRNA	28867213
D003633	Dichlorodiphenyl Dichloroethylene	Dichlorodiphenyl Dichloroethylene results in decreased methylation of IGF2 gene	25187598; 28867213;
C000944	dicrotophos	dicrotophos results in increased expression of IGF2 mRNA	28302478
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of IGF2 mRNA	29753845
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of IGF2 mRNA	22610992
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of IGF2 mRNA	12127304
D004052	Diethylnitrosamine	Diethylnitrosamine affects the expression of IGF2 mRNA	20387270
D004052	Diethylnitrosamine	Diethylnitrosamine results in decreased expression of IGF2 mRNA	19542621
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of IGF2 protein	12532445
D004054	Diethylstilbestrol	[Diethylstilbestrol co-treated with sodium arsenite] results in increased expression of IGF2 mRNA	19665456
D004054	Diethylstilbestrol	Diethylstilbestrol results in increased expression of IGF2 mRNA	21658437
D004128	Dimethylnitrosamine	Dimethylnitrosamine results in increased expression of IGF2 mRNA	17032414
D015237	Dinoprost	Dinoprost affects the expression of IGF2 mRNA	20484870
D015237	Dinoprost	Dinoprost results in decreased expression of IGF2 mRNA	20484870
D004317	Doxorubicin	Doxorubicin results in decreased expression of IGF2 mRNA	29803840
D004533	Egtazic Acid	Egtazic Acid results in decreased susceptibility to IGF2 protein	16485066
C070609	EMD 53998	EMD 53998 analog results in increased expression of IGF2 mRNA	24977338
C045651	epigallocatechin gallate	epigallocatechin gallate results in decreased expression of IGF2 mRNA	20346928
D004958	Estradiol	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of IGF2 mRNA	19619570
D004958	Estradiol	[Estradiol co-treated with TGFB1 protein] results in increased expression of IGF2 mRNA	30165855
D004958	Estradiol	Estradiol promotes the reaction [Resveratrol results in decreased secretion of IGF2 protein]	16037384
D004958	Estradiol	Estradiol results in increased expression of IGF2 mRNA	19619570
D004958	Estradiol	Estradiol results in increased expression of IGF2 protein	18191855
D004958	Estradiol	Estradiol results in increased secretion of IGF2 protein	16037384
D004958	Estradiol	IGF2 protein results in increased chemical synthesis of Estradiol	24055520
D004958	Estradiol	Resveratrol inhibits the reaction [Estradiol results in increased secretion of IGF2 protein]	16037384
D004958	Estradiol	Tamoxifen inhibits the reaction [Estradiol results in increased secretion of IGF2 protein]	16037384
D004958	Estradiol	Estradiol results in decreased expression of IGF2 mRNA	21703268
C010452	estradiol-17 beta-benzoate	estradiol-17 beta-benzoate affects the expression of IGF2 mRNA	15059950
D004967	Estrogens	Estrogens results in increased expression of IGF2 mRNA	14669216
D004967	Estrogens	Tetrachlorodibenzodioxin inhibits the reaction [Estrogens results in increased expression of IGF2 mRNA]	14669216
D004970	Estrone	IGF2 protein results in increased chemical synthesis of Estrone	24055520
D000431	Ethanol	Ethanol affects the expression of IGF2 mRNA	11772933
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of IGF2 mRNA	16872691
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of IGF2 protein	15817916
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of IGF2 mRNA	17555576
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of IGF2 mRNA	15576828; 15834898; 17557909;
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of IGF2 mRNA	23129252
D017313	Fenretinide	Fenretinide results in decreased expression of IGF2 mRNA	28973697
C017690	fenvalerate	fenvalerate results in decreased expression of IGF2 mRNA	28369636
C053629	fluoroaluminum	fluoroaluminum results in increased expression of IGF2 mRNA	11996908
C053629	fluoroaluminum	fluoroaluminum results in increased expression of IGF2 protein	11996908
D005473	Fluoxetine	Fluoxetine results in decreased expression of IGF2 mRNA	17033635
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of IGF2 mRNA	20938992
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of IGF2 gene	20938992
D004397	Fonofos	Fonofos results in increased methylation of IGF2 promoter	22847954
D005620	Freund's Adjuvant	Freund's Adjuvant inhibits the reaction [Urethane affects the expression of IGF2 mRNA]	12810352
D005620	Freund's Adjuvant	[Urethane co-treated with Freund's Adjuvant] results in increased expression of IGF2 mRNA	12400877
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in decreased expression of BAD protein modified form]]	23419388
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased cleavage of and results in increased activity of CASP3 protein]]	23419388
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of BCL2L1 protein]]	23419388
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of GNAQ protein]]	23419388
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [dan-shen root extract inhibits the reaction [IGF2 protein mutant form results in increased expression of IGF2R protein]]	23419388
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [dan-shen root extract results in decreased susceptibility to IGF2 protein mutant form]	23419388
C039281	furan	furan results in decreased expression of IGF2 mRNA	25539665
D019833	Genistein	Genistein results in decreased expression of IGF2 mRNA	21048042
C004312	glycidol	glycidol results in increased expression of IGF2 mRNA	24395379
D006046	Gold	Gold inhibits the reaction [IGF2 protein binds to IGF1R protein]	9648927
C070163	homobrassinolide	homobrassinolide results in increased expression of IGF2 mRNA	21491949
D006854	Hydrocortisone	IFNB1 protein inhibits the reaction [IGF2 protein results in increased secretion of Hydrocortisone]	23507702
D006854	Hydrocortisone	IGF2 protein results in increased secretion of Hydrocortisone	23507702
D006861	Hydrogen Peroxide	Hydrogen Peroxide inhibits the reaction [CTCF protein binds to and results in decreased methylation of and results in decreased expression of IGF2 gene]	24558376
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in increased methylation of and results in increased expression of IGF2 gene	24558376
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of IGF2 mRNA	28628672
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of IGF2 mRNA	28628672
D007213	Indomethacin	[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in increased expression of IGF2 mRNA	28628672
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in increased expression of IGF2 mRNA	27392435
C544151	jinfukang	jinfukang results in increased expression of IGF2 mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of IGF2 mRNA	26644586
C410337	K 7174	K 7174 results in decreased expression of IGF2 mRNA	24086573
D007811	Lanthanum	Lanthanum inhibits the reaction [IGF2 protein results in increased import of Calcium]	2442157
D007854	Lead	Lead results in decreased methylation of IGF2 gene	26115033
C008261	lead acetate	lead acetate results in decreased expression of IGF2 mRNA	25596546
C008261	lead acetate	lead acetate results in decreased methylation of IGF2 gene	25596546
C008261	lead acetate	lead acetate results in decreased expression of IGF2 protein	24200854
C008261	lead acetate	lead acetate affects the expression of IGF2 mRNA	21864555
C017461	lead nitrate	lead nitrate affects the reaction [IGF2 affects the expression of MT1 mRNA]	11891201
C017461	lead nitrate	lead nitrate affects the reaction [IGF2 affects the expression of MT2 mRNA]	11891201
D008070	Lipopolysaccharides	Lipopolysaccharides results in decreased expression of IGF2 mRNA	12057914
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of IGF2 mRNA	16448778
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of IGF2 protein	16448778
D008070	Lipopolysaccharides	Tretinoin inhibits the reaction [Lipopolysaccharides results in increased expression of IGF2 mRNA]	16448778
D008070	Lipopolysaccharides	Tretinoin inhibits the reaction [Lipopolysaccharides results in increased expression of IGF2 protein]	16448778
C025340	manganese chloride	manganese chloride results in decreased methylation of IGF2 gene	27913844
D008687	Metformin	[Metformin co-treated with IGF2 protein] results in decreased expression of IGF1R mRNA	21664031
D008687	Metformin	[Metformin co-treated with IGF2 protein] results in decreased expression of IGF2R mRNA	21664031
D008687	Metformin	[Metformin co-treated with IGF2 protein] results in decreased expression of INSR mRNA	21664031
D008687	Metformin	[Metformin co-treated with IGF2 protein] results in increased phosphorylation of AKT1 protein	21664031
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of IGF2 mRNA	20938992
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of IGF2 gene	20938992
C005219	methyl cellosolve	methyl cellosolve results in increased expression of IGF2 mRNA	19643169
D008748	Methylcholanthrene	alpha-naphthoflavone inhibits the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to IGF2 promoter]]	29094188
D008748	Methylcholanthrene	alpha-naphthoflavone inhibits the reaction [Methylcholanthrene results in increased acetylation of IGF2 promoter]	29094188
D008748	Methylcholanthrene	alpha-naphthoflavone inhibits the reaction [Methylcholanthrene results in increased expression of IGF2 mRNA]	29094188
D008748	Methylcholanthrene	alpha-naphthoflavone inhibits the reaction [Methylcholanthrene results in increased methylation of IGF2 promoter]	29094188
D008748	Methylcholanthrene	Methylcholanthrene promotes the reaction [AHR protein binds to IGF2 promoter]	29094188
D008748	Methylcholanthrene	Methylcholanthrene results in increased acetylation of IGF2 promoter	29094188
D008748	Methylcholanthrene	Methylcholanthrene results in increased expression of IGF2 mRNA	29094188
D008748	Methylcholanthrene	Methylcholanthrene results in increased methylation of IGF2 promoter	29094188
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in decreased expression of IGF2 mRNA	23634900
D009532	Nickel	Nickel results in decreased susceptibility to IGF2 protein	16485066
C022838	nickel chloride	nickel chloride affects the expression of IGF2 mRNA	22546817
C017557	nickel subsulfide	nickel subsulfide results in increased expression of IGF2 mRNA	21086188
D009538	Nicotine	Nicotine results in increased expression of IGF2 mRNA	29486207
D009543	Nifedipine	Nifedipine results in decreased susceptibility to IGF2 protein	16485066
C007350	nitrofen	Dexamethasone inhibits the reaction [nitrofen results in increased expression of IGF2 mRNA]	10370016
C007350	nitrofen	Dexamethasone inhibits the reaction [nitrofen results in increased expression of IGF2 protein]	10370016
C007350	nitrofen	nitrofen results in decreased expression of IGF2 protein	24352370
C007350	nitrofen	nitrofen results in increased expression of IGF2 mRNA	10370016
C007350	nitrofen	nitrofen results in increased expression of IGF2 protein	10370016
C007350	nitrofen	Tretinoin inhibits the reaction [nitrofen results in decreased expression of IGF2 protein]	24352370
D018817	N-Methyl-3,4-methylenedioxyamphetamine	N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of IGF2 mRNA	20188158
C025589	ochratoxin A	ochratoxin A results in decreased expression of IGF2 mRNA	19287073
D000077150	Oxaliplatin	[Oxaliplatin co-treated with Topotecan] results in increased expression of IGF2 mRNA	25729387
C029341	oxophenylarsine	oxophenylarsine results in decreased localization of IGF2 protein	9145794
D010100	Oxygen	Oxygen deficiency results in increased expression of IGF2 mRNA	20862257
D019308	Palmitic Acid	Palmitic Acid results in increased expression of IGF2 mRNA	17658692
D000077767	Panobinostat	Panobinostat results in increased expression of IGF2 mRNA	26272509
D010269	Paraquat	Paraquat results in increased expression of IGF2 mRNA	21371552
D010278	Parathion	Parathion results in increased methylation of IGF2 promoter	22847954
D010400	Penicillin G	Penicillin G results in decreased expression of IGF2 mRNA	24737281
C046012	pentanal	pentanal results in increased expression of IGF2 mRNA	26079696
D010455	Peptides	Peptides inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]	24055520
D010455	Peptides	Peptides results in decreased susceptibility to IGF2 protein	24055520
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in decreased expression of IGF2 protein	26178269
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased methylation of IGF2 gene	27553991
D037342	Pertussis Toxin	Pertussis Toxin inhibits the reaction [IGF2 protein results in increased import of Calcium]	2442157
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of IGF2 mRNA	26272509
D010672	Phenytoin	Phenytoin results in increased expression of IGF2 mRNA	9988880
C032279	phthalic acid	phthalic acid analog results in decreased methylation of IGF2 gene	29513082
D059808	Polyphenols	Polyphenols results in decreased expression of IGF2 mRNA	16293270
C045362	prochloraz	prochloraz results in increased expression of IGF2 mRNA	20805220
D011374	Progesterone	Progesterone affects the localization of IGF2 protein	22085906
D011374	Progesterone	Progesterone results in increased expression of IGF2 mRNA	18497975
C045950	propiconazole	propiconazole results in increased expression of IGF2 mRNA	21278054
C005556	propionaldehyde	propionaldehyde results in increased expression of IGF2 mRNA	26079696
C573121	ProstaCaid	ProstaCaid results in decreased expression of IGF2 mRNA	21468543
C513428	pyrachlostrobin	pyrachlostrobin results in increased expression of IGF2 mRNA	27029645
D011794	Quercetin	Quercetin results in decreased expression of IGF2 mRNA	20658310
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride results in increased expression of IGF2 mRNA	15576828
D000077185	Resveratrol	Resveratrol results in increased expression of IGF2 mRNA	25866375
D000077185	Resveratrol	Estradiol promotes the reaction [Resveratrol results in decreased secretion of IGF2 protein]	16037384
D000077185	Resveratrol	Resveratrol affects the expression of IGF2 mRNA	16037384; 16393696;
D000077185	Resveratrol	Resveratrol inhibits the reaction [Estradiol results in increased secretion of IGF2 protein]	16037384
D000077185	Resveratrol	Resveratrol results in decreased secretion of IGF2 protein	16037384
D000077185	Resveratrol	Resveratrol results in increased expression of and results in increased secretion of IGF2 protein	16037384
D000077185	Resveratrol	Resveratrol results in increased expression of IGF2 protein	16393696
D000077185	Resveratrol	[Resveratrol results in increased expression of IGF2 protein] which results in increased secretion of CTSD protein	16393696
D000077185	Resveratrol	Tamoxifen inhibits the reaction [Resveratrol results in increased secretion of IGF2 protein]	16037384
D012402	Rotenone	Rotenone results in decreased expression of IGF2 mRNA	27900601
C093642	SB 203580	SB 203580 inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]	24055520
C093642	SB 203580	SB 203580 results in decreased susceptibility to IGF2 protein	24055520
D012822	Silicon Dioxide	Silicon Dioxide analog results in decreased expression of IGF2 mRNA	25895662
D020123	Sirolimus	Sirolimus results in decreased expression of IGF2 mRNA	20622751
D020123	Sirolimus	Sirolimus results in decreased expression of IGF2 protein	20622751
C017947	sodium arsenite	sodium arsenite results in increased expression of IGF2 mRNA	12016162
C017947	sodium arsenite	[Diethylstilbestrol co-treated with sodium arsenite] results in increased expression of IGF2 mRNA	19665456
C017947	sodium arsenite	sodium arsenite affects the expression of IGF2 mRNA	16507464
C017947	sodium arsenite	sodium arsenite results in decreased expression of IGF2 mRNA	17451858
C017947	sodium arsenite	sodium arsenite results in increased expression of IGF2 mRNA	17077188
C017947	sodium arsenite	sodium arsenite results in decreased expression of IGF2 mRNA	16876216
C017947	sodium arsenite	sodium arsenite results in increased expression of IGF2 mRNA	11241755
D000077210	Sunitinib	Sunitinib results in decreased expression of IGF2 mRNA	31533062
D013605	T-2 Toxin	T-2 Toxin results in increased expression of IGF2 mRNA	31299295
D013629	Tamoxifen	Tamoxifen inhibits the reaction [Estradiol results in increased secretion of IGF2 protein]	16037384
D013629	Tamoxifen	Tamoxifen inhibits the reaction [Resveratrol results in increased secretion of IGF2 protein]	16037384
D013629	Tamoxifen	Tamoxifen results in decreased secretion of IGF2 protein	16037384
D013629	Tamoxifen	Tamoxifen affects the expression of IGF2 mRNA	17555576
D000077204	Temozolomide	IGF2 mRNA affects the susceptibility to Temozolomide	16365179
C012568	terbufos	terbufos results in increased methylation of IGF2 promoter	22847954
D013739	Testosterone	Testosterone results in decreased expression of IGF2 protein	15817916
D013739	Testosterone	Testosterone results in increased expression of IGF2 mRNA	21703268
D013749	Tetrachlorodibenzodioxin	[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of IGF2 mRNA	19619570
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of IGF2 mRNA	19619570
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of IGF2 mRNA	15056799
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of IGF2 mRNA	21570461; 27284320;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of IGF2 mRNA	14960483
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased methylation of IGF2 gene	14960483
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the methylation of IGF2 gene	26455773
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin inhibits the reaction [Estrogens results in increased expression of IGF2 mRNA]	14669216
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin promotes the reaction [CEBPB protein binds to IGF2 promoter]	21777668
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of IGF2 mRNA	26455773; 31063829;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of IGF2 protein	26455773; 31063829;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased methylation of IGF2 gene	17407073
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of IGF2 mRNA	17407073; 21777668;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of IGF2 protein	17407073; 21777668;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased methylation of IGF2 gene	31063829
C009424	tetramethrin	tetramethrin inhibits the reaction [IGF2 protein results in increased import of Calcium]	2442157; 2539779;
D013853	Thioacetamide	Thioacetamide results in increased expression of IGF2 mRNA	17997003
C402769	tipifarnib	tipifarnib results in increased expression of IGF2 mRNA	16403772
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of IGF2 protein	30291989
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in decreased expression of IGF2 mRNA	30579903
C024746	tobacco tar	Decitabine inhibits the reaction [tobacco tar results in decreased expression of IGF2 mRNA]	19559774
C024746	tobacco tar	tobacco tar results in decreased expression of IGF2 mRNA	19559774
D019772	Topotecan	[Oxaliplatin co-treated with Topotecan] results in increased expression of IGF2 mRNA	25729387
D014118	Toxins, Biological	Toxins, Biological affects the expression of IGF2 mRNA	19682533
D014212	Tretinoin	Tretinoin metabolite results in increased expression of IGF2 mRNA	15982314
D014212	Tretinoin	Tretinoin promotes the reaction [IGF2R binds to and results in increased secretion of IGF2 protein modified form]	16680587
D014212	Tretinoin	Tretinoin results in decreased activity of IGF2 protein	16680587
D014212	Tretinoin	Tretinoin results in decreased expression of IGF2 mRNA	23724009
D014212	Tretinoin	[bisphenol F co-treated with Tretinoin] results in decreased expression of IGF2 mRNA	30951980
D014212	Tretinoin	Tretinoin results in increased expression of IGF2 mRNA	16604517
D014212	Tretinoin	Tretinoin inhibits the reaction [Lipopolysaccharides results in increased expression of IGF2 mRNA]	16448778
D014212	Tretinoin	Tretinoin inhibits the reaction [Lipopolysaccharides results in increased expression of IGF2 protein]	16448778
D014212	Tretinoin	Tretinoin inhibits the reaction [nitrofen results in decreased expression of IGF2 protein]	24352370
D014212	Tretinoin	Tretinoin results in increased expression of IGF2 mRNA	24977338
C011559	tributyltin	tributyltin results in decreased expression of IGF2 mRNA	29505797
D014238	Trichloroacetic Acid	Trichloroacetic Acid results in decreased methylation of IGF2 gene	15036762
C012589	trichostatin A	trichostatin A results in increased expression of IGF2 mRNA	24935251; 26272509;
D014260	Triclosan	Triclosan results in increased expression of IGF2 mRNA	30510588
C015559	trimellitic anhydride	trimellitic anhydride results in decreased expression of IGF2 mRNA	19042947
D014520	Urethane	Freund's Adjuvant inhibits the reaction [Urethane affects the expression of IGF2 mRNA]	12810352
D014520	Urethane	IFNG protein promotes the reaction [Urethane results in increased expression of IGF2 mRNA]	12810352
D014520	Urethane	[Urethane co-treated with Freund's Adjuvant] results in increased expression of IGF2 mRNA	12400877
D014635	Valproic Acid	Valproic Acid results in increased expression of IGF2 mRNA	24935251; 26272509; 28001369;
D014635	Valproic Acid	Valproic Acid results in increased expression of IGF2 mRNA	24896083
D014635	Valproic Acid	Valproic Acid results in increased expression of IGF2 mRNA	29427782
C025643	vinclozolin	vinclozolin affects the expression of IGF2 mRNA	19015723
C017963	vinyl carbamate	Budesonide inhibits the reaction [vinyl carbamate results in decreased methylation of IGF2 protein]	15824018
C017963	vinyl carbamate	vinyl carbamate results in decreased expression of IGF2 mRNA	17849452
C017963	vinyl carbamate	vinyl carbamate results in decreased methylation of IGF2 protein	15824018
D000077337	Vorinostat	Vorinostat results in increased expression of IGF2 mRNA	26272509
D000077191	Wortmannin	Wortmannin inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]	24055520
D000077191	Wortmannin	Wortmannin results in decreased susceptibility to IGF2 protein	24055520
D015032	Zinc	Zinc promotes the reaction [IGF2 protein binds to IGF1R protein]	9648927
D015034	Zinc Oxide	Zinc Oxide affects the expression of IGF2 mRNA	28648595
D019287	Zinc Sulfate	Zinc Sulfate results in decreased expression of IGF2 mRNA	21167956

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0025	Alternative splicing
KW-0119	Carbohydrate metabolism
KW-0165	Cleavage on pair of basic residues
KW-0903	Direct protein sequencing
KW-1015	Disulfide bond
KW-0242	Dwarfism
KW-0313	Glucose metabolism
KW-0325	Glycoprotein
KW-0339	Growth factor
KW-0372	Hormone
KW-0497	Mitogen
KW-0892	Osteogenesis
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0964	Secreted
KW-0732	Signal

Interpro

InterPro ID	InterPro Term
IPR022334	IGF2
IPR013576	IGF2_C
IPR016179	Insulin-like
IPR022350	Insulin-like_growth_factor
IPR036438	Insulin-like_sf
IPR022353	Insulin_CS
IPR022352	Insulin_family

PROSITE

PROSITE ID	PROSITE Term
PS00262	INSULIN

Pfam

Pfam ID	Pfam Term
PF08365	IGF2_C
PF00049	Insulin

Gene: IGF2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction